A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 272 participants.
Also called NCT07755150
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 272 participants
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
- Registry
-
NCT07755150
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07755150. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-30 (anticipated); primary completion 2027-10-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- DA-302168S
- Intervention (Drug)
- Placebo of DA-302168S
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Record details
- Record id
cardio:ct-nct07755150- Content hash
e1fe93027bf6320a615ae5cac293d1b59d5a5d5894418761be1e3eb4bfe5ad28